Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

bluebird bio Inc (NASDAQ:BLUE)

36.67
Delayed Data
As of 4:15pm ET
 -4.10 / -10.06%
Today’s Change
35.37
Today|||52-Week Range
171.24
-42.90%
Year-to-Date
A Biotech Stock Turnaround Requires an Alzheimer's Drug Miracle
4:33pm / TheStreet.com - Paid Partner Content
Better Buy: Agenus Inc. vs. bluebird bio
Jun 24 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close40.77
Today’s open40.80
Day’s range36.62 - 41.95
Volume1,292,739
Average volume (3 months)1,104,345
Market cap$1.5B
Dividend yield--
Data as of 4:15pm ET, 06/27/2016

Growth & Valuation

Earnings growth (last year)-162.84%
Earnings growth (this year)-26.36%
Earnings growth (next 5 years)-23.75%
Revenue growth (last year)-44.62%
P/E ratioNM
Price/Sales158.14
Price/Book1.77

Competitors

 Today’s
change
Today’s
% change
RDUSRadius Health Inc-1.62-4.60%
NVAXNovavax Inc-0.39-5.86%
OPHTOphthotech Corp-2.02-3.89%
AXONAxovant Sciences Ltd-0.29-2.47%
Data as of 4:15pm ET, 06/27/2016

Financials

Next reporting dateAugust 10, 2016
EPS forecast (this quarter)-$1.50
Annual revenue (last year)$14.1M
Annual profit (last year)-$166.8M
Net profit margin-1,184.62%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Nick Leschly
Chief Medical Officer
David M. Davidson
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Partner Offers

Search for Jobs